NEW YORK (GenomeWeb News) – The Center for Medicare Services is beginning to take a closer look at genetic tests and will consider if some of these molecular tests should be approved for coverage under the program.

CMS will review evidence on genetic tests, assess their preventive value, and will consider gene expression and pharmagoconemic tests for coverage decisions, according to CMS's Chief Medical Officer, Barry Straube, who spoke recently at a Department of Health and Human Services meeting in Washington, DC.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.